---
schema_version: "secwatch.filing_event.v1"
accession: "0000064803-23-000003"
form_type: "8-K"
ticker: "CVS"
cik: "0000064803"
company_name: "CVS HEALTH Corp"
filed_at: "2023-01-09T23:59:59+00:00"
generated_at: "2026-06-20T18:22:09.318770+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# CVS reaffirms FY2022 Adj. EPS guidance at high end; FY2023 Adj. EPS $8.70-$8.90

## Summary
- Reaffirmed FY2022 Adj. EPS guidance $8.55-$8.65; expects high end on lower share count.
- Expects to exceed FY2022 revenue guidance of $309B-$314B.
- Reaffirmed FY2023 Adj. EPS guidance $8.70-$8.90, excluding Signify Health acquisition.
- Repurchased ~15M shares in Q4 2022 at avg $99.99; entered $2B ASR effective Jan 3, 2023.
- MA membership growth low-to-mid-single digit % in 2023; individual MA below expectations, exchange memberships >750k.

## SEC filing metadata
- accession: 0000064803-23-000003
- form_type: 8-K
- ticker: CVS
- cik: 0000064803
- company_name: CVS HEALTH Corp
- filed_at: 2023-01-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/64803/000006480323000003/0000064803-23-000003-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/64803/000006480323000003/cvs-20230109.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000064803-23-000003
- JSON: https://secwatch.observer/filing/0000064803-23-000003.json
- Plain text: https://secwatch.observer/filing/0000064803-23-000003.txt

## Key facts
- Earnings Releases
  CVS HEALTH Corp reported full-year 2023 results: EPS $8.70 to $8.90. Guidance reaffirmed.
  - Period: full-year 2023
  - EPS: $8.70 to $8.90
  - Guidance: reaffirmed
  - Result: guidance update
  source text: The Company will also reaffirm its projected full-year 2023 Adjusted EPS guidance range of $8.70 to $8.90
  evidence_url: https://www.sec.gov/Archives/edgar/data/64803/000006480323000003/0000064803-23-000003-index.htm
- Earnings Releases
  CVS HEALTH Corp reported full-year 2022 results: EPS $8.55 to $8.65. Guidance reaffirmed.
  - Period: full-year 2022
  - EPS: $8.55 to $8.65
  - Guidance: reaffirmed
  - Result: guidance update
  source text: the Company will disclose that it has reaffirmed its estimated full-year 2022 Adjusted earnings per share ("EPS") guidance range of $8.55 to $8.65
  evidence_url: https://www.sec.gov/Archives/edgar/data/64803/000006480323000003/0000064803-23-000003-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.